Unraveling complexity. Harnessing insights.

Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways.

We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway.

Celcuity announces positive topline Phase 3 data

Topline data is now available from VIKTORIA-1, a clinical trial evaluating the investigational drug gedatolisib in breast cancer.

LEARN MORE

Providing options.
Delivering hope.

We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

Our third-generation cellular analysis platform unravels complex oncogenic activity molecular tests can’t detect.

See our approach

Our discoveries create new potential applications for targeted therapies.

View our pipeline

Our comparative analyses of different drugs use live patient tumor cells, revealing opportunities to develop first-in-class drugs.

Learn about Gedatolisib

News

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

See all news